TITLE:
The Short- and Long-Term Effect of Liraglutide on the Beta Cell Function in Type 2 Diabetic Patients
AUTHORS:
Toshinobu Suzuki, Koichi Hirai, Yingchao Chen, Kunihiko Hashimoto
KEYWORDS:
Glucagon-Like Peptide 1, Oral Glucose Tolerance Test, Insulin Secretion, Insulin Sensitivity, Type 2 Diabetes
JOURNAL NAME:
Journal of Diabetes Mellitus,
Vol.4 No.4,
November
11,
2014
ABSTRACT: Glucagon-like peptide 1
(GLP-1) is a hormone, inducing glucose-dependent stimulation of insulin
secretion from beta cells. Liraglutide acts as a GLP-1 receptor agonist. To
assess the effect of liraglutide on the beta cell function, we performed oral
glucose tolerance tests in 7 subjects with type 2 diabetes before and after
treatment of liraglutide. Moreover, we performed same study again in 4 subjects
at 6 months after induction. Liraglutide significantly increased area under the
Curve (AUC) of plasma insulin
level after glucose loading and significantly decreased AUC of plasma glucose
level, compared with before induction. HOMA-beta was significantly increased,
whereas insulinogenic index was not changed. HOMA-R was not affected but
Matsuda index was significantly decreased after induction of liraglutide.
Disposition index was not altered significantly, but tendency of improvement
was observed. Glucose tolerance tests revealed that those effects of
liraglutide were continued for 6 months after induction. These results showed
that treatment of liraglutide could improve insulin secretion but early phase
of insulin secretion was not improved. The results suggest that liraglutide is
likely to improve beta-cell function, but this effect is still inadequate by
six-month treatment.